Active — Not RecruitingPhase 4

Acceptability of the HPV Vaccine and Anal HPV in Transgender Women and Men Who Have Sex With Men: A Pilot Study

Argentina101 participantsStarted 2024-10-09

Plain-language summary

Protocol Title: "Acceptability of the Human Papillomavirus (HPV) Vaccine and Anal HPV in Transgender Women (TGW) and Men Who Have Sex with Men (MSM): A Pilot Study.

Who can participate

Age range18 Years – 90 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. stable antiretroviral treatment during the last 6 months and with undetectable viral load (depending on the method used for measurement) within the same period (the participant can bring a laboratory report carried out in the last 6 months). Regarding ART, a change associated with toxicity or simplification may be allowed before 12 weeks of the selection visit, with undetectable VL between 12 weeks and the selection visit; and
✓. CD4 cell count ≥ 200 cells/ml in the last 6 months (participant can bring a laboratory report from the last 6 months)

What they're measuring

Proportion of people receiving the first dose of vaccine and of people receiving 3 doses of HPV vaccine among those recruited.

Timeframe: 12 months

Trial details

NCT IDNCT06588257

SponsorFundación Huésped

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04-09

View on ClinicalTrials.gov More HPV trials